Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ARQ 197 in Combination with Erlotinib in CYP2C19 Poor Metabolizer Patients with Advanced/Recurrent Non-Small-Cell Lung Cancer
jRCT2080221318Phase 1
- Sponsor
- Kyowa Kirin
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of tivantinib and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Kyowa Kirin.
02
Drugs
tivantiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221318.